Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

New approach could treat infertility caused by abnormal GnRH secretion

Reports suggest that at least 25% of ovarian disorders are due to dysfunction of the brain mechanism in the hypothalamus that controls the gonadotropin-releasing hormone (GnRH), which is a molecule that governs the reproductive function in men and women by regulating the release of a range of reproductive hormones into the body, particularly gonadotropins, from the pituitary gland, which is located underneath the brain.

12 Mar 2021

Phase 2 clinical trial is now open at Columbia to test gene therapy for dry macular degeneration

A phase 2 clinical trial is underway at Columbia University and NewYork-Presbyterian to test an investigational gene therapy for dry age-related macular degeneration, a progressive, chronic eye disease with no cure and a leading cause of blindness in the United States.

9 Mar 2021

Delayed second dose strategy with mRNA vaccines may reduce COVID-19 mortality, say researchers

An interesting new preprint shows that even if countries are forced to delay the second dose of the current vaccines administered against SARS-CoV-2, to arrest the ongoing COVID-19 pandemic, the cumulative mortality would still fall significantly.

3 Mar 2021

Novel SARS-CoV-2 spike vaccine candidate produces strong neutralizing response in vivo

A new study by researchers at Mahidol University in Bangkok, Thailand, reports a COVID-19 vaccine candidate called HexaPro in producing neutralizing antibodies against the SARS-CoV-2 spike protein in an animal model.

3 Mar 2021

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent and Delphi Genetics today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.

26 Feb 2021

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent and Delphi Genetics today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.

26 Feb 2021

Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2?

The study began with the generation of recombinant (r)SA11 rotaviruses, into which segment 7 modified RNAs were introduced. These encoded sequences for the non-structural protein NSP3 and some parts of the viral spike.

23 Feb 2021

Could measles virus vectors be used for a new COVID-19 vaccine?

A research team at the Institut Pasteur in France describes the successful development of such a vaccine utilizing a measles virus vector.

18 Feb 2021

Viruses can use freshwater sources as vector for transmission, study suggests

Water is a necessity for all life but its availability can be limited. In geographical areas experiencing dry seasons, animals congregate near the few freshwater sources, often reaching large densities.

15 Feb 2021

Cell-selective nanotherapy can help treat atherosclerotic plaques

Percutaneous coronary intervention (PCI), commonly known as angioplasty with a stent, opens clogged arteries and saves lives. Despite its benefit in treating atherosclerosis that causes coronary artery disease, this common minimally-invasive procedure still poses severe complications for some patients.

11 Feb 2021

CRISPR genomic editing to obtain more productive and nutritive plant varieties

New study by the IBMCP of the UPV university facilitates the use of the CRISPR genomic editing technique on plants.

8 Feb 2021

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

The phase 3 human trial is the last stage of clinical evaluation, showing how effective and safe a drug or vaccine is. In this case, the Gam- Sputnik V showed a consistent strong protective effect across all participant age groups.

3 Feb 2021

COVID-19 vaccine should be recommended to patients with Parkinson’s disease, experts say

Patients with Parkinson's disease (PD) and healthcare professionals caring for them have expressed concerns about the COVID-19 vaccine's efficacy and safety in the specific context of PD and its symptomatic treatment.

3 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021

What do we know about the SARS-CoV-2 vaccines so far?

A new study surveys what we know so far about SARS-CoV-2 vaccine candidates from advanced clinical trials.

27 Jan 2021

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic.

14 Jan 2021

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.

14 Jan 2021

Atmospheric particulate matter may influence the transmission and evolution of SARS-CoV-2

A recent study conducted at the University of Malta Medical School, Malta, has revealed that a drop in the level of particulate matter 2.5 (PM2.5), which are airborne pollutant particles with a diameter of 2.5 micrometer, in the atmosphere due to lockdown is associated with the arrival of a newer variant of SARS-CoV-2, which has eventually displaced the original virus after lockdown.

12 Jan 2021

Gene therapy can effectively treat mice with tuberous sclerosis complex, shows study

Patients with tuberous sclerosis complex, a genetic disorder characterized by the growth of noncancerous tumors in multiple organs of the body, have limited treatment options.

8 Jan 2021

Viral Vector News and Research

Further Reading

New approach could treat infertility caused by abnormal GnRH secretion

Phase 2 clinical trial is now open at Columbia to test gene therapy for dry macular degeneration

Delayed second dose strategy with mRNA vaccines may reduce COVID-19 mortality, say researchers

Novel SARS-CoV-2 spike vaccine candidate produces strong neutralizing response in vivo

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2?

Could measles virus vectors be used for a new COVID-19 vaccine?

Viruses can use freshwater sources as vector for transmission, study suggests

Cell-selective nanotherapy can help treat atherosclerotic plaques

CRISPR genomic editing to obtain more productive and nutritive plant varieties

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

COVID-19 vaccine should be recommended to patients with Parkinson’s disease, experts say

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

What do we know about the SARS-CoV-2 vaccines so far?

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

Atmospheric particulate matter may influence the transmission and evolution of SARS-CoV-2

Gene therapy can effectively treat mice with tuberous sclerosis complex, shows study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News